WO2024252184 - ANTI-CLDN18_2 ANTIBODY AND AN IN VITRO DIAGNOSTIC KIT
National phase entry:
Publication Number
WO/2024/252184
Publication Date
12.12.2024
International Application No.
PCT/IB2024/000278
International Filing Date
07.06.2024
Title **
[English]
ANTI-CLDN18_2 ANTIBODY AND AN IN VITRO DIAGNOSTIC KIT
[French]
ANTICORPS ANTI-CLDN18_2 ET TROUSSE DE DIAGNOSTIC IN VITRO
Applicants **
JIANGSU AOSAIKANG BIOPHARMACEUTICAL CO., LTD.
766 Kening Road
Jiangning Science Park
Nanjing, Jiangsu 211112, CN
Inventors
WEN, Yong
c/o Jiangsu Aosaikang Biopharmaceutical Co., Ltd.
766 Kening Road
Jiangning Science Park
Nanjing, Jiangsu 211112, CN
HOU, Guwei
c/o Jiangsu Aosaikang Biopharmaceutical Co., Ltd.
766 Kening Road
Jiangning Science Park
Nanjing, Jiangsu 211112, CN
FU, Song
c/o Jiangsu Aosaikang Biopharmaceutical Co., Ltd.
766 Kening Road
Jiangning Science Park
Nanjing, Jiangsu 211112, CN
SUN, Jiye
c/o Jiangsu Aosaikang Biopharmaceutical Co., Ltd
766 Kening Road
Jiangning Science Park
Nanjing, Jiangsu 211112, CN
Priority Data
202310675165.8
07.06.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1131 | |
| EPO | Filing, Examination | 4962 | |
| Japan | Filing | 595 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 2710 |
Total: 9972 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure relates to kits comprising an anti claudin 18.2 antibody that are useful for assessing expression claudin 18.2 expression in a biological sample obtained from a human, e.g., a human patient having cancer.[French]
La présente divulgation concerne des trousses comprenant un anticorps anti-claudine 18.2 qui sont utiles pour évaluer l'expression de la claudine 18.2 dans un échantillon biologique obtenu à partir d'un être humain, par exemple, un patient humain atteint d'un cancer.